It subsequently stimulated the transactivation of MDR1 and stemness-related factors, including SOX2, OCT4, and NANOG, thereby enhancing HCC stemness and the resistance to sorafenib and doxorubicin [12]. The gene discussed is NANOG; the disease is hepatocellular carcinoma.